Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell
- Conditions
- Cancer of the MouthOropharynx Squamous Cell Carcinoma
- Interventions
- Behavioral: Symptom QuestionnairesBehavioral: Dysphagia Inventory QuestionnaireBehavioral: Activity Bands
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02663583
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy
Not Applicable
Active, not recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Barium SwallowBehavioral: QuestionnairesBehavioral: Neurocognitive ExamsDevice: Expiratory Muscle Strength Training (EMST) DeviceDevice: Digital Manometer
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 175
- Registration Number
- NCT02662907
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02662608
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Phase 1
Completed
- Conditions
- Malignant GliomaRecurrent Brain NeoplasmGlioblastomaRecurrent GlioblastomaCytomegalovirus PositiveGliosarcoma
- Interventions
- Biological: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytesOther: Laboratory Biomarker AnalysisProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT02661282
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
Phase 2
Terminated
- Conditions
- Malignant Chest Wall NeoplasmRecurrent Breast CarcinomaRecurrent Inflammatory Breast CarcinomaStage IV Inflammatory Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Talimogene Laherparepvec
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02658812
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Early Phase 1
Active, not recruiting
- Conditions
- Advanced Fallopian Tube CarcinomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaCarcinomatosisFallopian Tube High Grade Serous AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaStage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT02659241
- Locations
- 🇺🇸
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT02652871
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT02649764
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Randomized AmnioFix Study During Radical Prostatectomy
Phase 2
Withdrawn
- Conditions
- Prostate Cancer
- Interventions
- Procedure: Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)Behavioral: QuestionnaireBiological: AmnioFix®
- First Posted Date
- 2016-01-01
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02645591
Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib
Phase 2
Completed
- Conditions
- Diffuse Large B-Cell Lymphoma Unclassifiable
- Interventions
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT02636322
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath